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Purpose:  To  investigate  the  contribution  of  matrix  metalloproteinases  (MMPs)  to  recurrent  corneal  melting  in
keratoconjunctivitis sicca associated with primary Sjörgen’s syndrome (pSS).
Methods: One native melted cornea and ten melted corneal grafts from two patients with severe pSS were used. The
presence of MMPs (1, 2, 3, 7, 8, 9, and 13) was detected using indirect enzyme immunohistochemistry. The active forms
of MMP 2 and 9 and MMP 3 and 7 were examined by gelatin and casein zymography, respectively. The concentrations
of active MMP 1 were measured using an activity assay. Eleven unaffected corneas served as controls.
Results: 
MMP 3 and 8 positivity, in the corneal epithelium of melted corneas. Intense MMP 1 and 9 staining, moderate MMP 2,
3, and 8 staining, and weak MMP 7 staining were found in the anterior stroma. The posterior stroma revealed intense
MMP 1, moderate MMP 3 and 9, and weak MMP 2, 7, and 8 positivity. Immunostaining of the endothelium was moderate
for MMP 9 and weak for MMP 1, 2, 3, 7, and 8. MMP 13 was negative in all but four melted specimens, where weak-to-
moderate staining was found in the epithelium and stroma. Control corneas revealed moderate MMP 1 and 2 and weak
MMP 8 staining in the epithelium, weak MMP 2 staining in the anterior stroma, and weak MMP 1 and 8 staining in the
endothelium. Significantly elevated MMP 1 activity and extremely elevated MMP 9 activity were found in most of the
tested pathological specimens, compared to healthy controls, where no activity of the two enzymes was present. Markedly
elevated MMP 2 activity was found in 2 of 11 specimens, compared to normal tissue. The inactive form of MMP 3 was
detected in half of the tested specimens, and inactive MMP 7 in all melted corneas. Active MMP 3 and 7 were found in
one melted sample. Neither of these MMPs was found in any of the control specimens.
Conclusions: The increased expression and elevated activity of a wide range of MMPs in melted cornea samples from
two patients diagnosed with pSS confirm that these enzymes contribute to the tissue destruction, leading to serious
consequences such as corneal perforation and loss of vision.
Primary  Sjögren’s  syndrome  (pSS)  is  a  systemic
autoimmune disease with an estimated prevalence of only
about  0.5%.  It  is  characterized  by  the  destruction  of  the
lachrymal  and  salivary  glands,  resulting  in
keratoconjunctivitis sicca syndrome (KCS) and xerostomia
[1-3]. There is lymphocytic infiltration in the exocrine glands
and  the  production  of  various  autoantibodies  [1,4,5].
Extraglandular systemic manifestations may involve several
tissues and organs [3,6-8]. The ethiopathogenesis of pSS is
complex;  environmental  factors  are  thought  to  trigger
inflammation in individuals with a genetic predisposition, but
the exact underlying cause remains unknown [2,5].
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Most patients do not exhibit severe ocular complications.
Those that need to attend ophthalmology clinics have been
found to suffer, in addition to dry eye, from bacterial keratitis,
pannus formation, and sterile corneal melting [9-11].
Corneal  melting  (keratolysis)  is  a  rare,  occasionally
recurrent condition. It is characterized by the development of
epithelial  defects  and  the  gradual  reduction  of  stromal
components, which may lead to descemetocele formation and
subsequent perforation of the cornea [12-15]. Less than 20
cases of sterile corneal melting or corneal ulcers in association
with pSS have been described in the literature [11,16,17].
Although the exact mechanism of corneal melting has not
been elucidated, it is often linked to the overexpression of
matrix  metalloproteinases  (MMPs),  which  are  considered
mainly responsible for the destruction and consequent loss of
the  extracellular  matrix  (ECM)  [18-21].  Most  of  these
endopeptidases are synthesized as inactive proenzymes that
are activated by proteolytic cleavage [22,23]. On the basis of
substrate  specificity,  sequence  similarity,  and  domain
organization,  MMPs  are  classified  into  six  groups:
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The average values of the staining intensity revealed very intense MMP 1, intense MMP 2, 7, and 9 and moderatecollagenases,  gelatinases,  stromelysins,  matrilysins,
membrane type MMPs, and others. In the cornea, MMPs can
be produced by keratocytes, epithelial cells, monocytes, and
macrophages [20,24-27].
In this study, seven MMPs representing four main groups
of these endopeptidases were investigated in extremely severe
cases  of  KCS  associated  with  pSS.  These  included
collagenases (MMPs 1, 8, 13) capable of cleaving collagen
types I, II, and III [23]; gelatinases (MMP 2 and 9) capable of
degrading collagen types IV, V, and VI, as well as decorin,
fibronectin, and laminin [28-30]; and stromelysins (MMP 3)
and matrilysins (MMP 7), which have similar substrates—
type  IV  collagen,  procollagens,  collagen  cross-links,
fibronectin, and laminin [22,23]. We report recurrent corneal
melting in two patients with severe pSS and its relation to the
activity of major MMPs.
METHODS
The study adhered to the tenets set out in the Declaration of
Helsinki. Local Ethics Committee approval was granted. All
melted  explants  were  obtained  from  the  Department  of
Ophthalmology,  General  Teaching  Hospital  and  the  1st
Faculty of Medicine, Charles University, in Prague.
Case report 1: A 77-year-old patient was diagnosed with
pSS elsewhere at the age of 71. She tested positive for anti-
SS-A/Ro,  anti-SS-B/La,  and  antinuclear  antibodies.  No
extraglandular  manifestations  were  noted.  Systemic
immunosuppression  administered  to  the  patient  included
various  combinations  of  cyclophosphamide,  prednisolon,
azathioprin,  methylprednisolon,  cyclosporine  A,  and
mycophenolate  mofetil.  Upon  first  examination  in  our
Department of Ophthalmology in 2002 at age 74, the patient
presented  with  bilateral  severe  dry  eye  syndrome.  In  the
course of three years, she suffered from numerous episodes of
corneal melting, requiring a number of surgical procedures.
In  the  right  eye,  seven  penetrating  keratoplasties  were
performed (6 grafts were used as specimens S2, S3, S4, S6,
S7, and S8), along with a number of amniotic membrane
transplants,  tarsorrhaphies,  and  other  surgeries  aimed  at
improving the condition of the ocular surface and preventing
progressive  tissue  melting.  In  the  left  eye,  the  patient
underwent four penetrating keratoplasties (her native cornea
was used as specimen S1 and one graft as specimen S5), as
well as other, similar, surgeries to the right eye. Despite all
the  measures  undertaken,  her  condition  could  not  be
controlled, and it led to bilateral blindness.
Case report 2: In case 2, the symptoms related to pSS
started  at  the  age  of  46  when  swollen  salivary  glands,
xerostomia, and severe dry eye symptoms were noted by the
patient. Histopathology from a labial salivary gland biopsy
sample showed focal sialadenitis that was consistent with a
diagnosis of pSS. The patient tested positive for rheumatoid
factor,  antinuclear  antibodies,  and  Scl70  antibodies.
Subsequently  she  also  developed  arthralgias.  Systemic
immunosuppression  therapy  was  started  at  the  age  of  50.
Initially, the patient was treated with oral prednisolon; later,
various  combinations  of  methotrexate,  cyclophosphamide,
and  methylprednisolon  were  added.  Upon  first  ocular
examination at age 46, she had signs of moderate dry eye
syndrome in both eyes. She gradually developed severe dry
eye syndrome bilaterally. When the patient reached the age of
58,  the  first  signs  of  peripheral  ulcerative  keratitis  were
observed in the right eye, followed three years later in the left
eye. She rapidly developed corneal thinning, and underwent
her first keratoplasty in the right eye at the age of 59 (specimen
S9),  followed  by  numerous  other  procedures  due  to
complications related to melting of the graft, including two
penetrating keratoplasties (specimens S10 and S11). At the
last follow up visit, her visual acuity was full light projection
in the right eye and hand movements with full projection of
light in the left eye.
Specimen preparation: Eleven melted corneal specimens
of the two patients were processed within three h after surgery.
Eleven unaffected donor corneal buttons (mean age 59.8±16.9
years) that were unsuitable for transplantation, due to their low
endothelial cell density, served as controls (obtained from the
Ocular Tissue Bank, General Teaching Hospital, Prague). The
mean time from the donor’s deaths to enucleation was 15 h,
and the mean time from death to tissue freezing was 17 h. All
specimens  were  dissected  into  two  halves,  snap-frozen  in
liquid nitrogen, and stored at 70 ºC. Prior to freezing, one-half
was embedded in Optimal Cutting Temperature Compound
(Christine  Gröpl,  Tulln,  Austria).  Before  the  activity
assessment, the specimens were thawed, were homogenized
in cacodylate buffer (0.1 M cacodylic acid, 0.15 M NaCl, 0.01
M CaCl2, 1.5 mM NaN3, 0.005% Triton X-100, and 0.1 nM
ZnCl2), and underwent protein extraction for 2 days at 4 °C.
Next, they were centrifuged for 30 min at 10,000× g; the
supernatants were removed and frozen at -20 °C.
Indirect enzyme immunohistochemistry: Cryosections (7
μm thick) from each of the control and melted specimens were
placed on gelatin-coated glass slides (four per slide), fixed
with cold acetone for 10 min, rinsed in phosphate-buffered
saline  (PBS),  and  incubated  for  30  min  in  3%  hydrogen
peroxide in PBS. After washing in PBS, the specimens were
blocked for 30 min with 2.5% bovine serum albumin in PBS.
Then the slides were incubated for 1 h at room temperature
with the primary antibodies listed in Table 1. Subsequently,
the slides were washed in PBS, and the secondary antibodies
(polyclonal rabbit anti-mouse IgG and swine anti-rabbit IgG
conjugated with biotin, 1:200; DakoCytomation, Glostrup,
Denmark) were applied for 1 h. After rinsing in PBS (three
times  for  5  min  each),  streptavidin/HRP  (1:250;
DakoCytomation, Glostrup, Denmark) was added for 30 min.
Finally,  the  slides  were  developed  with  0.06%  3,3'-
diaminobenzidine  tetrahydrochloride  (Fluka,  Buchs,
Switzerland) in PBS, counterstained with Harris hematoxylin,
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Negative control specimens (primary antibody omitted) were
included on each slide. Samples of human placenta (MMP 1,
2, 3, and 7) and breast carcinoma (MMP 7, 8, 9, and 13) were
used as positive controls [31,32]. The intensity of the signal
was assessed separately in the epithelium, anterior stroma,
posterior  stroma,  and  endothelium  using  five  grades  of
positivity: 0 (negative), 1 (weak), 2 (moderate), 3 (intense), 4
(very intense). The mean average positivity was calculated
from at least three sections of two independent experiments.
Gelatin and casein substrate zymography: All specimens
(native cellular protein quantity,  8.5 μg) were treated with
sample  buffer  (1.5%  sodium  dodecyl  sulfate  [SDS],  15%
glycerol, and 0.005% bromphenol blue). Gelatin and casein
zymography were performed for the detection of MMP 2 and
9, and MMP 3 and 7, respectively, using 10% polyacrylamide
gel containing 0.1% gelatin (AppliChem GmbH, Darmstadt,
Germany) and 12% gel copolymerized with 0.09% β-casein
(Sigma-Aldrich,  St.  Louis,  MO).  In  brief,  20  μl  of  each
specimen were loaded onto the gels, and SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) was performed at 200 V at
4 °C for gelatin zymography, and at 20 mA at 4 °C for casein
zymography. After electrophoresis, the gels were twice rinsed
in 2.5% Triton X-100 for 30 min at room temperature to
remove the SDS, then incubated in reaction buffer (50 mM
Tris-HCl, pH 7.5; 200 mM NaCl,; 5 mM CaCl2; and 0.02% 23
lauryl  ether[Brij-35])  at  37  °C  overnight  to  allow  the
proteinases to digest their substrates. The gels were stained
for 1 h at room temperature in 0.5% Coomassie brilliant blue
R-250 (Serva Electrophoresis, Heidelberg, Germany) in 40%
methanol and 10% acetic acid, then destained with a mixture
of 40% methanol and 10% acetic acid. Proteolytic activities
appeared as clear bands of lysis against a dark background of
stained gelatin or casein.
Matrix  metalloproteinase  1  activity  assays:  The
concentrations of the active forms of MMP 1 were determined
using  a  commercial  kit  (Amersham  matrix
metalloproteinase-1  Biotrak  Activity  assay  system,
Amersham Biosciences, Amersham, UK) according to the
manufacturer’s protocol. The values of the color reaction of
the assays were read at 405 nm in a SUNRISE ELISA Reader
(Tecan Trading AG, Männedorf, Switzerland). The activity of
MMP 1 in ten samples was determined by interpolation from
the standard curve. The activity assay could not be performed
in S3, due to the lack of sufficient specimens.
Statistical analysis: The Mann-Whitney U test was used
to  analyze  the  differences  between  the  control  and  the
experimental  groups.  A  p  value  <0.05  was  considered  to
indicate statistical significance.
RESULTS
Localization  of  individual  matrix  metalloproteinases  in
melted and control specimens: All control corneas exhibited
regular morphology, with a five- to six-layered epithelium.
Severe damage was observed in most of the pathological
specimens,  ranging  up  to  the  complete  absence  of  the
epithelial layers and, in some specimens, a partly dissolved
Bowmann’s layer and a partly dissolved edge of the anterior
stroma in the area of the lesions.
The levels of staining of antibodies against particular
MMPs  in  control  samples  were  averaged.  No  prominent
differences in MMP staining were found among the individual
control specimens for any of the MMPs tested. Moderate
staining for MMP 1 and 2, and weak staining for MMP 8, were
detected in the epithelium. A weak signal for MMP 2 was
observed adjacent to Bowman’s layer, in approximately one-
sixth of the anterior stroma. Weak staining was also found for
MMP 1 and 8 in the endothelium of the control specimens.
Immunostaining for MMP 3, 7, 9, and 13 was completely
negative in all layers of all control corneas (Figure 1).
The  staining  intensity  of  different  MMPs  in  melted
specimens is summarized in Table 2. Immunohistochemical
staining of both the control and melted specimens is shown in
Figure 1. In the melted specimens, stronger staining for MMP
9 was found in the epithelial fragments of all tested corneas,
if they were not destroyed. It was also found for MMP 1, 2,
3, and 7 in almost all melted corneas, compared to the controls.
Increased staining for MMP 1 and 9 was found in the whole
stroma in all tested corneas, and for MMP 2, 3, 7, and 8 in
almost all melted grafts, compared to the controls. Positivity
staining for MMP 2, 3, and 7 was detected in the endothelium
of a few melted specimens, while staining for MMP 9 was
observed in all melted grafts. MMP 13 revealed only a weak-
to-moderate staining pattern in the epithelial fragments and in
the stroma of four specimens and in the endothelium of one
specimen.
TABLE 1. MATRIX METALLOPROTEINASE DETECTING ANTIBODIES USED FOR INDIRECT IMMUNOHISTOCHEMISTRY.
Antibody Catalogue number Concentration Company
Polyclonal rabbit anti-human MMP 1 AB8105 1:300 Chemicon Intl. Inc.
Monoclonal mouse anti-human MMP 2 MAB13431 1:350 Chemicon Intl. Inc.
Polyclonal rabbit anti-human MMP 3 29576 1:50 AnaSpec Inc., San Jose, CA
Monoclonal mouse anti-human MMP 7 MAB13414 1:150 Chemicon Intl. Inc.
Polyclonal rabbit anti-human MMP 8 AB8115 1:300 Chemicon Intl. Inc.
Monoclonal mouse anti-human MMP 9 MAB3309 1:150 Chemicon Intl. Inc.
Monoclonal mouse anti-human MMP 13 MAB13424 1:50 Chemicon Intl. Inc.
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zymography,  2  of  the  11  melted  specimens  (S1  and  S2)
displayed extremely high levels of both the proenzyme and
active form of MMP 2, compared to the control corneas.
Figure  1.  Immunohistochemical
localization  of  matrix
metalloproteinases  in  melted  and
control corneas. Immunohistochemical
localization of MMP 1, 2, 3, 7, 8, 9, and
13 in representative images of melted
corneal  specimens  obtained  from
patients with pSS (cases 1 and 2) and
from  control  corneas.  Original
magnification, 100×. Ep = epithelium,
AS = anterior stroma, PS = posterior
stroma, En = endothelium.
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Detection of metalloproteinase activity:Levels  of  MMP  9  proenzyme  and  the  active  form  were
extremely high in seven (S4, S6-S11) melted specimens and
prominent  in  one  (S5).  Three  melted  specimens  (S1-S3)
revealed  faint  bands  for  both  forms  of  MMP  9,  and  two
controls did so for MMP 9 proenzyme only (Figure 2A).
Casein zymography revealed neither the proenzyme nor
the  active  enzyme  of  MMP  3  or  7  in  any  of  the  control
specimens. Negligible levels of the proform of MMP 3 were
found in five melted specimens (S1, S2, S6, S7, and S9). Both
forms, the proform and active MMP 3, were detected in one
sample (S5) only. Nine melted corneas (S2-S10) revealed high
levels of MMP 7 proenzyme and its intermediate cleavage
product. Two samples (S1 and S11) revealed low levels. Very
low levels of active MMP 7 were found in one specimen (S7)
only (Figure 3).
Matrix metalloproteinase 1 activity assay—The active
form of MMP 1 was found in eight of ten melted corneas at
concentrations ranging from 0.08 to 3.03 ng/ml (p=0.0011).
No activity was detected in the control specimens (Table 3).
DISCUSSION
In this study, we present two cases with pSS undergoing
rapidly  progressive  recurrent  corneal  melting  despite  all
available  treatment,  including  immunosuppression.  We
obtained two series of tissue specimens from the eyes of one
repeatedly grafted patient: six consecutive ones from the right
eye, and two from the left . We also obtained one series of
three consecutive tissue samples from the right eye of another
patient  with  pSS.  Our  findings  clearly  demonstrated  the
increased presence of MMP 1, 2, 3, 7, 8, and 9, as well as
higher activity of MMP 1, 2, 3, 7, and 9, in the pathological
pSS specimens, compared to the control tissue.
To the best of our knowledge, this is the first time that
these  enzymes  have  been  studied  in  corneal  melting
associated with pSS. Previously, differences in corneal MMP
expression  were  detected  in  patients  with  keratolysis
associated  with  rheumatoid  arthritis  [21],  an  autoimmune
disorder that has some overlapping clinical features with pSS,
and in patients with melted corneas after cataract surgery and
photorefractive keratectomy, both of which are treated with
diclophenac [18,19,33]. Our study demonstrated a statistically
TABLE 2. THE IMMUNOHISTOCHEMICAL LOCALIZATION OF INDIVIDUAL MMPS IN THE CORNEAL SPECIMENS OBTAINED FROM TWO PATIENTS WITH PSS (S1-8
AND S9-11 RESPECTIVELY) AND THE AVERAGE VALUES OF IMMUNOHISTOCHEMICAL STAINING IN ALL MELTED SPECIMENS (S) AND CONTROLS (C).
MMP Corneal layer
Sample
S1 S2 S3          S4          S5          S6 S7 S8 S9 S10 S11         S         C
MMP 1 Ep 4 4 DDD 2 D 4 4 D D 4 2
  AS 3 4323144423 3 0
  PS 2 3224234413 3 0
  En 0 3 D D 0 0 D D2D D 1 1
MMP 2 Ep 3 3 DDD 4324 D D 3 2
  AS 4 2204223323 2 1
  PS 3 2101003021 1 0
  En 2 100320D100 1 0
MMP 3 Ep 2 2 DDD 202323 2 0
  AS 2 2102142402 2 0
  PS 1 0202142402 2 0
  En D 00010 D D2D D 1 0
MMP 7 Ep 0 4 DDD 4340 D 4 3 0
  AS 0 1203213002 1 0
  PS 0 1203113002 1 0
  En D D D 021 D D0D D 1 0
MMP 8 Ep 2 4 DDD 1022 D D 2 1
  AS 2 1123202124 2 0
  PS 0 1023102114 1 0
  En D D0D200D2 0 D 1 1
MMP 9 Ep 2 4 DDD 1224 D 3 3 0
  AS 3 3134423123 3 0
  PS 1 3012323114 2 0
  En 4 2D121 D D1D0 2 0
Ep 0 0 DDD 1010 D D 0 0
  AS 0 0102101000 0 0
  PS 0 0102001000 0 0
  En D 00010 D D 0 0 D 0 0
The scale used for the intensity of the signal: 0 - negative, 1 - weak, 2 - moderate, 3 - intense, 4 - very intense positivity. 
D = destroyed tissue. Ep = epithelium, AS = anterior stroma, PS = posterior stroma and En = endothelium.
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MMP 13significant higher activity of MMP 1 and a high expression of
MMP 9 in the corneal epithelium and stroma. Both these
results conform to the immunostaining results of others [18,
19,21,33].  As  for  MMP  2,  its  overexpression  in  both  the
epithelium and stroma, as well as its higher activity, have been
reported in other investigations [18,33]. However, one study
showed only a weak presence of MMP 2 in the stroma of a
patient who had undergone cataract surgery and had been
treated with diclophenac [19]. Our results also demonstrated
variability in the MMP 2 expression in melted corneas, since
only 2 of the 11 specimens revealed a considerable increase
in  its  activity,  compared  to  the  controls.  One  possible
explanation for this phenomenon is that MMP 2 activity is
limited to a short period in the melting process, unlike the
other MMPs. This hypothesis is supported by delays in the
activity increase of this enzyme in corneas after alkali burn,
suggesting its role to be in the regeneration and remodeling of
the corneal ECM, rather than in the degradation process [34,
35].
A  marked  increase  of  MMP  3  in  the  epithelium  and
stroma of melted grafts has been detected previously, in the
stroma of a patient after photorefractive keratectomy treated
with  topical  diclofenac  [18].  Although  we  confirmed  the
presence of MMP 3 in melted corneas as well, we were not
able to detect a prominent increase in its activity. This may be
due  to  the  low  sensitivity  of  casein  zymography  [36].
Unfortunately, there was not enough material available to
perform other, more sensitive methods of MMP 3 detection.
Our study is the first to demonstrate the presence and
activity of MMP 7 in melted corneas. Additionally, casein
zymography showed a large quantity of inactive MMP 7 in all
tested specimens and active MMP 7 in one specimen. We
suggest that MMP 7 is an important element in the degradation
of the corneal basement membrane in corneal melting, as it
Figure 2. Gelatin zymography of matrix
metalloproteinases 2 and 9 in melted and
control corneas. Melted specimens (A)
S1  and  S2  showed  extremely  high
levels, and specimens S7, S9, and S11
considerable  levels,  of  both  the
proenzyme  (67  KDa  band)  and  the
active form of MMP 2 (62 kDa band).
Levels of MMP 9 proenzyme (95 kDa
band) and the active form (82 kDa band)
were extremely high in S4 and S6-S11,
and prominent in S5. Weak bands for
both  MMP  9  forms  were  found  in
specimens  S1-S3.  In  control  samples
(B),  a  moderate  level  of  the  MMP  2
proenzyme  was  present  in  all
specimens, whereas the active form of
MMP 2 was either not present or very
faint,  except  in  samples  C1,  C3,  and
C11. As for MMP 9 proenzyme, only C3
and C7 showed faint bands.
Figure 3. Casein zymography of matrix
metalloproteinases  3  and  7  in  melted
specimens. Very slight bands of only the
MMP 3 proform (59 kDa) were detected
in five melted specimens (S1, S2, S6,
S7, and S9) and of both the proform and
active MMP 3 (47 kDa) in one specimen
(S5). High levels of MMP 7 proenzyme
(30 kDa) and its intermediate cleavage
product (28 kDa) were detected in nine
melted  corneas,  S2-S10,  and  weak
bands  of  these  two  MMP  7  inactive
forms  were  found  in  two  melted
specimens (S1 and S11). A very slight
band of active MMP 7 (20 kDa) was
found in one specimen only (S7).
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layer.
Up to now, MMP 8 has been studied only in one melted
cornea following cataract surgery, where it was found to be
considerably  increased  in  both  the  epithelium  and  stroma
[19]. In our study, we found a weak-to-moderate presence of
this enzyme in both the epithelium and stroma. We attribute
such differences to the fact that the occurrence of MMP 8 in
the stroma depends on the presence of neutrophils [22], the
distribution of which may vary among melted corneas [19,
37,38].
We also found a weak increase in the presence of MMP
13  in  the  stroma  of  three  samples.  To  the  best  of  our
knowledge, no other study has previously evaluated MMP 13
in melted corneas. The expression of MMP 13 has only been
described in the epithelium of wounded corneas [39] and in
the epithelium and stroma of corneas with keratoconus [40].
We did not observe any trend towards an increase or
decrease  of  individual  MMP  expression  over  time,  or  of
disease progression, in any of the consecutive patient samples.
Instead, the combination of MMPs detected seemed to be
completely different in each specimen. This could have a
number of causes, such as the different stages of melting at
which the explants were obtained. It may also be that the
expression  of  MMPs  showed  local  variations  within
individual specimens, depending on the distance from the
central melting point. It should be noted, however, that the
staining and activity of individual MMPs were similar for
consecutive sections obtained from each specimen.
MMPs  in  patients  suffering  from  primary  SS  have
previously been studied in tears [41], saliva [42], and salivary
glands [43,44]. It has been suggested that the activation of
these enzymes is the key factor responsible for the corneal
barrier disruption, as well as for the destruction of the salivary
glands [42,44-46]. Given the characteristic features of pSS,
there  may  be  more  than  one  mechanism  leading  to  the
induction  of  different  MMPs.  For  example,  lymphocytic
infiltrates  secrete  pro-inflammatory  cytokines  [2]  that  are
known  to  initiate  MMP  expression  in  various  tissues  via
different pathways [22]. Up-regulated IL-1β, found in the
tears  of  pSS  patients  [41],  could  also  play  a  role  in  the
expression  of  MMPs,  especially  MMP  9,  via  mitogen-
activated protein kinase signaling pathways [47]. Finally, a
mouse  model  of  dry  eye  has  shown  that  desiccation  and
hyperosmolar stress may lead to the induction of MMPs via
the stimulation of proinflammatory cytokines [45,47]. We
hypothesize that in advanced cases of pSS, such as in our
patients, MMPs may be upregulated to such an extent that the
epithelial barrier is substantially degraded, followed by the
dissolution  of  its  basement  membrane  (caused  mainly  by
MMP 3, 7, and 9) and the gradual degradation of the stroma,
involving  MMP  1,  3,  7,  8,  and  9.  After  the  stroma  is
completely lost, a descemetocele is formed, and finally the
integrity of the whole cornea is disrupted.
The fact that none of the disease-modifying therapies
used  in  these  patients  was  effective  in  decreasing  MMP
production and keratolysis suggests that different treatment
strategies with anti-MMP therapies should be considered in
similar cases, such as using recombinant tissue inhibitors of
MMPs [48] or chemical inhibitors of MMPs. For example, the
TNF-α antagonist infliximab has been shown to inhibit one of
the activators of MMP production [49]. Direct inhibition of
MMPs  can  be  achieved  by  tetracyclines,
medroxyprogesteron, or ion-chelating agents such as cysteine
or  thylenediaminetetraacetic  acid  [50-53].  Finally,  an
alternative approach in keratolysis treatment could be focused
on the recovery and strengthening of the collagen structure by
collagen cross-linking [54].
Our study examined extremely severe cases of corneal
melting  associated  with  pSS,  and  has  elucidated  the
participation of some MMPs in this destructive process. It
confirmed that these enzymes play an important role in the
severe  degradation  of  corneal  tissue  leading  to  corneal
perforation and loss of vision. Their involvement suggests that
MMP inhibitors may play an important role in the treatment
of this condition.
TABLE 3. MMP 1 ACTIVITY ASSAY. THE CONCENTRATIONS OF THE ACTIVE FORMS OF MMP 1 IN MELTED CORNEAL TISSUE WERE DETERMINED BY
INTERPOLATION FROM THE STANDARD CURVE.
Specimen Concentration of active MMP 1 (ng/ml)
S1 0.69
S2 0.08
S4 0.23
S5 0.7
S6 0.23
S7 0.0
S8 0.39
S9 0.0
S10 3.03
S11 1.22
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